Oral anticoagulants used for the primary treatment of venous thromboembolism (VTE) include warfarin and the more recently introduced direct oral anticoagulants (DOACs), including rivaroxaban, apixaban, dabigatran and edoxaban. Information on the comparative safety of these medications in routine clinical practice is lacking. We identified patients with diagnoses for VTE and prescriptions for oral anticoagulants using claims data from a large U.S. insurance database from 2012 to 2017. Marginal structural logistic models were used to examine associations between type of oral anticoagulant and risk of all-cause mortality. Of 62,431 enrolees in this analysis, 51% were female and the mean age was 61.9 years. Initial oral anticoagulant prescriptions were for warfarin (n ¼ 35,704), rivaroxaban (n ¼ 21,064) and apixaban (n ¼ 5,663). A total of 1,791 deaths occurred within 6 months of the initial oral anticoagulant prescription. Risk of all-cause mortality was not associated with having a prescription for warfarin versus any DOAC or between any head-to-head DOAC comparisons. Also, associations generally did not vary when stratified by VTE type, sex, age, co-morbidities (including renal disease) or anti-platelet medication use. In this observational study, the associations with all-cause mortality comparing DOACs versus warfarin agree with results from previous clinical trials and observational studies, while the associations for headto-head DOAC comparisons provide new information on the comparative safety of DOACs. Our findings suggest that other criteria such as patient preference, cost, recurrent VTE risk or bleeding risk should be used when determining the choice of anticoagulant for the primary treatment of VTE.
Introduction
Evidence from phase III clinical trials demonstrates that during the primary treatment of venous thromboembolism (VTE) (i.e., first 3-6 months after the event), direct oral anticoagulants (DOACs; dabigatran, rivaroxaban, apixaban and edoxaban) are non-inferior to vitamin K antagonist (VKA) therapy for preventing recurrent, symptomatic VTE and VTE-related death. [1] [2] [3] [4] [5] [6] However, results from clinical trials may have limitations generalizing to routine clinical practice. 7 Also, trials of new drugs are often underpowered to detect differences in risk for important safety outcomes, such as all-cause mortality. Indeed, the 10th Edition Antithrombotic Guidelines by the American College of Chest Physicians rates the quality of evidence for each DOAC versus VKA therapy for the prevention of all-cause mortality as 'moderate' due to lack of precision. 8 For these reasons, observational cohort studies have recently begun to assess the comparative safety and effectiveness of DOACs versus VKA therapy in the community-wide setting. [9] [10] [11] [12] [13] Two studies compared the safety of rivaroxaban versus VKA therapy with respect to all-cause mortality, although the number of events was relatively small ( 125 total deaths in each study); 11, 12 another study had a larger number of deaths, but made a pooled comparison of any DOAC (rivaroxaban, apixaban or dabigatran) versus VKA therapy. 13 We are unaware of any observational studies of the primary treatment of VTE with all-cause mortality as an outcome that have compared the use of apixaban separately versus VKA therapy or compared DOACs in a head-to-head fashion.
In this study, we used administrative claims data from a large U.S. insurance database to compare the relative risk (RR) of all-cause mortality between patients with prescriptions for rivaroxaban, apixaban and VKA therapy (warfarin) for the primary treatment of VTE.
Materials and Methods

Study Population and Exposure Ascertainment
This study involves a retrospective analysis of claims data from OptumLabs ® Data Warehouse, which includes de-identified claims data for privately insured and Medicare Advantage enrolees in a large, private, U.S. health plan. The database contains longitudinal health information on enrolees, representing a diverse mixture of ages, races/ethnicities and geographic regions across the United States. The health plan provides comprehensive full insurance coverage for physician, hospital and prescription drug services. 14 All enrolee data available for research is pre-existing and de-identified in compliance with the Health Insurance Portability and Accountability Act of 1996 and hence is exempted from institutional review board approval.
We identified a cohort of enrolees between 2 November 2012 and 31 March 2017 who had (1) at least 1 inpatient, 1 emergency room or 2 outpatient (separated by at least a week but less than a year) claims for VTE and (2) at least 1 pharmacy claim for an oral anticoagulant (warfarin, dabigatran, rivaroxaban, apixaban or edoxaban) filled within 7 days before or 31 days after the initial VTE diagnosis. Because of small numbers, patients using dabigatran or edoxaban were not included in this study. The date of first anticoagulant prescription falling within the specified time range around the VTE claim was defined as the index date. The time window of interest began on 2 November 2012 because this was the date of Food and Drug Administration approval of rivaroxaban for the treatment of VTE. VTE cases were identified based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or ICD-10-CM diagnosis codes shown in ►Supplementary Table S1 (available in the online version). The positive predictive value of VTE cases identified using the list of ICD-9-CM claims is roughly 75 to 85% [15] [16] [17] [18] and is higher when additionally requiring an anticoagulant pharmacy claim. 19, 20 The validity for identifying warfarin users via pharmacy claims is excellent (sensitivity: 94%, positive predictive value: 99%). 21 Presently, no validation data exist on the accuracy of DOAC claims, but accuracy should be comparable.
Outcome Ascertainment
The outcome of interest, all-cause mortality, was ascertained based on two data sources. First, enrolees in the cohort were linked with the Social Security Administration (SSA) Death Master File, allowing the capture of both out-of-hospital and in-hospital deaths. Linkage to the SSA Death Master File can be based on several identifying criteria, including name, date of birth and Social Security number. For this analysis, we required a match based on Social Security number to consider death present. Historically, the mortality information in the SSA Death Master File had adequate sensitivity (86%) and high specificity (100%). 22 However, since 2011 death information from state records has not been included in the SSA Death Master File, which is known to be now missing approximately 40% of deaths. 22 Therefore, we additionally used medical claims with a discharge status of 'expired' as a supplemental means of identifying in-hospital deaths.
Covariates
All covariates of interest were measured using information from up to 180 days of enrolment prior to and including the index date. Age and sex were determined from the medical or pharmacy claims on the index date. Geographic region (U.S. census region) was ascertained from insurance member coverage records. Co-morbid disease, frailty and concomitant medications are potentially important confounders to consider since they may influence treatment choice and mortality. Malignancy, renal disease, liver disease, obesity, coagulopathy and numerous other constituent variables of the Charlson and Elixhauser co-morbidity indices were selected as covariates based on pre-defined ICD-9-CM and ICD-10-CM diagnosis codes. 23 We also defined variables related to clinical manifestations of frailty, including abnormal gait, cachexia and use of durable medical equipment, based on pre-defined diagnosis and procedure codes. 24 See ►Supplementary Table S2 (available in the online version) for a full list of the co-morbidity and frailty variables included in this analysis. Pharmacy claims were used to identify concomitant or recent use of medications, including insulin, anti-diabetics, anti-hypertensives, statins, anti-platelets, celecoxib, narcotic analgesics and anti-neoplastics. Since aspirin is widely used over-the-counter, it was not included among the group of anti-platelet medications.
Exclusions
We made several exclusions due to having missing covariates or for other reasons. In particular, we excluded enrolees with a history of VTE due to the differing treatment recommendations for those with recurrent VTE. Similarly, including prevalent DOAC or warfarin users in the analysis may lead to bias, 25 so we excluded any participants with a prescription claim for an oral anticoagulant prior to the index date. Of the 93,999 enrolees identified as candidates for inclusion in the study, we excluded those who were less than 18 years old or whose sex or geographic region was unknown or missing (n ¼ 1,432), those who had a history of VTE or a previous pharmacy claim for an oral anticoagulant (n ¼ 13,557) and those with fewer than 90 days of continuous health plan enrolment prior to the index date (n ¼ 15,944).
Statistical Analysis
Baseline participant characteristics were presented by treatment group. All-cause deaths occurring by 3 and 6 months after the index date were identified. For the primary analysis, we used logistic regression to estimate marginal odds ratios (ORs) and 95% confidence intervals (CIs) for the association between oral anticoagulant use and all-cause mortality for six different comparisons: rivaroxaban versus warfarin, apixaban versus warfarin and apixaban versus rivaroxaban. For analyses involving apixaban, all enrolees with an index date before the date of the drug's approval for treating VTE (21 August 2014) were excluded. To mimic the intention-to-treat design of the randomized trials comparing DOACs to warfarin, we analysed enrolees according to the oral anticoagulant used at the index date regardless of whether they discontinued during followup, as has been done previously. 26 For every comparison, we fit two sets of models: unadjusted (crude) logistic regression and inverse-probability-of-treatment weighted (IPTW) marginal structural logistic models. 27 For the latter models, stabilized weights were calculated as the inverse of the conditional predicted probability of being prescribed the oral anticoagulant that was actually prescribed multiplied by the marginal prevalence of that oral anticoagulant. The conditional predicted probability of using an oral anticoagulant was estimated using logistic regression, in which the log-odds of using an oral anticoagulant was modelled as a function of age, age, 2 sex, U.S. census region, index date, index date, 2 diagnosis setting (inpatient or emergency room vs. outpatient), VTE type (pulmonary embolism [PE] vs. deep vein thrombosis [DVT] alone), the constituent co-morbidity and frailty variables and concomitant medications. We refer to this model as the exposure model. If certain anticoagulants are associated with a higher risk of out-of-hospital mortality, this may lead to differential outcome misclassification. 28, 29 So, as a sensitivity analysis, we estimated the associations for the six main comparisons using only the Death Master File data for the all-cause mortality outcome.
Because clinical trials and other observational studies have compared the risk of mortality for rivaroxaban and apixaban versus VKA therapy, we summarized these previous results with those from this study using inverse variance-weighted random effects meta-analysis. For the comparison of rivaroxaban versus VKA therapy, results are stratified by DVT/PE, in line with the design of the EINSTEIN trials. 2, 3 We also estimated the association between oral anticoagulant use and all-cause mortality using IPTW marginal structural logistic models stratified by specific covariates of interest, including by VTE type, sex, age, renal disease, liver disease, overweight and obesity and use of anti-platelet medications. We tested for evidence of multiplicative interaction on the log OR scale by including a cross-product term between the covariate and anticoagulant treatment. We also estimated the relative excess risk due to interaction (RERI) and 95% CIs as a measure of additive interaction, using the delta method to estimate standard errors, 30 since the additive scale may be the most important from a biological and public health perspective. 31 A super-additive (sub-additive) interaction, indicated by a RERI greater than (less than) than 0, means that the combined effect of the two exposures is larger (smaller) than the sum of the individual effects. Statistical analyses were performed using SAS, version 9.4 (SAS Institute, Cary, North Carolina, United States).
Results
The analyses that follow are based on a total of 62,431 enrolees diagnosed with VTE and prescribed an oral anticoagulant. The sample was 51% female, and the mean age was 61.9 years with a range from 18 to 89 years. Due to the small number of individuals older than 89 years, participants aged > 89 years were set to a value of 89 to preserve protected health information. The numbers of prescriptions for the initial oral anticoagulant were 35,704 for warfarin, 21,064 for rivaroxaban and 5,663 for apixaban. Because of small numbers, we did not include enrolees with an initial prescription for dabigatran (n ¼ 509) or edoxaban (n ¼ 19) in any subsequent analyses (there were 12 deaths in the dabigatran group and 0 deaths in the edoxaban group occurring within 6 months). When comparing warfarin versus DOAC users, warfarin users on average were older and had a higher prevalence of co-morbidities and concomitant medication use (►Table 1). For comparisons involving head-to-head comparisons of DOACs, apixaban users on average were the oldest and had the highest prevalence of co-morbidities, while rivaroxaban users on average were the youngest and had the lowest co-morbidity burden (►Supplementary Table S3 , available in the online version).
Among the 62,431 enrolees included in the analysis, we identified 1,213 (1.9%) all-cause deaths occurring within 3 months and 1,791 (2.9%) all-cause deaths occurring within and 6 months of the index date. Compared with warfarin users, the risk of all-cause mortality within 6 months was lower among rivaroxaban users (OR, 0.59, 95% CI, 0.53, 0.66) and apixaban users (OR, 0.81, 95% CI, 0.68, 0.97) in crude models (►Table 2). In IPTW models adjusting for demographics, co-morbidities and concomitant medications, the associations of rivaroxaban and apixaban with lower mortality versus warfarin were no longer present (OR, 0.97, 95% CI, 0.84, 1.11 for rivaroxaban vs. warfarin; OR, 0.91, 95% CI, 0.72, 1.15 for apixaban vs. warfarin). Associations were similar when the outcome was all-cause mortality within 3 months, although CIs were wider due to fewer events.
Compared with rivaroxaban users, the crude risk of 6-month all-cause mortality was higher among apixaban users (OR, 1.45, 95% CI, 1.19, 1.77), although this association was attenuated in the adjusted IPTW model (OR, 1.07, 95% CI, 0.86, 1.34; ►Table 2). In sensitivity analyses using only all-cause deaths from the Death Master File, associations were largely similar, although with wide CIs due to a decreased number of events (►Supplementary Table S4 , available in the online version).
In ►Fig. 1, we summarize the results from this study along with those from the phase III clinical trials and previous observational studies for comparisons of rivaroxaban and apixaban versus VKA therapy. Overall, there was no evidence of a difference in the risk of mortality for most comparisons. Among DVT patients, there was a little evidence suggesting possibly a lower RR of mortality with use of rivaroxaban versus VKA therapy (RR, 0.84, 95% CI, 0.62, 1.14), although with some heterogeneity (I 2 ¼ 55%) between studies. Oral anticoagulant use generally remained un-associated with 6-month all-cause mortality in models stratified by VTE type, sex, renal disease, liver disease, overweight and obesity or use of anti-platelet medications (►Fig. 2). For the comparison of apixaban versus warfarin, there was possible evidence of multiplicative interaction with age (p-value for interaction: 0.04); the risk of 6-month all-cause mortality was lower among apixaban users compared with warfarin users in those aged less than 65 years (OR, 0.58, 95% CI, 0.37, 0.90), whereas there was no association in those who were aged 65 years or older 
Discussion
In a large administrative dataset, there was no association between the anticoagulant prescribed (warfarin vs. any DOAC) and risk of all-cause mortality during the VTE primary treatment phase (i.e. over the first 3 or 6 months) after adjusting for demographics, co-morbidities and medication use. Similarly, in head-to-head DOAC comparisons, risk of all-cause mortality was similar regardless of the DOAC prescribed. Further, associations generally did not vary when stratified by VTE type, sex, age, co-morbidities or anti-platelet medication use, except for potentially a lower risk of mortality in younger individuals on apixaban versus warfarin or rivaroxaban. These data suggest that other criteria should be used when determining the choice of anticoagulant for the primary treatment of VTE, such as patient preference, cost, recurrent VTE risk or bleeding risk. This study provides valuable information for assessing the safety of oral anticoagulants with respect to how they have been prescribed in a U.S. routine clinical practice setting over the entire time period through which DOACs have been approved for treating VTE (2012-2017). To our knowledge, this study represents the largest comparison of rivaroxaban versus VKA therapy and apixaban versus VKA therapy with respect to risk of all-cause mortality in terms of total sample size and number of deaths. Our findings, that there were generally no differences in the risk of 3-or 6-month all-cause mortality for VTE patients with prescriptions for rivaroxaban and apixaban in comparison to VKA therapy, are in agreement with the results from the phase III clinical trials and previous observational studies, and our findings have not raised any additional safety risks with DOACs or warfarin in terms of all-cause mortality. [1] [2] [3] [4] 6, [11] [12] [13] Furthermore, this is the first study to compare DOACs in a head-to-head fashion (apixaban vs. rivaroxaban) with respect to risk of all-cause mortality. Our sample size was large for this comparison, allowing us to estimate effect measures with reasonable precision. We did not find any differences in mortality risk for apixaban versus rivaroxaban. While dabigatran and edoxaban are approved for the treatment of VTE, the need for an initial parental treatment phase puts these medications at a great disadvantage to apixaban and rivaroxaban which offer all-oral treatments for VTE. It is unlikely that any advantages of dabigatran and edoxaban (such as lack of metabolism through cytochrome P450 3A4) will outweigh this disadvantage in clinical practice.
Caution should be exercised when interpreting the interaction data with apixaban and age. There is no a priori hypothesis as to why apixaban would have a lower mortality in younger individuals compared with either rivaroxaban or warfarin. While the findings could be true, they may also be due to chance or impacted by unaccounted confounding. After 3 weeks at a higher dose, rivaroxaban is administered once daily to treat VTE, despite having a shorter half-life than apixaban (administered twice daily). More efficient renal metabolism in younger individuals could lead to increased VTE-related mortality. This effect was seen with edoxaban where the efficacy was reduced in individuals with normal renal function in the trial which led to its approval for stroke and systemic embolization prevention in atrial fibrillation. 32 Compared with warfarin, apixaban is known to have a lower risk of major bleeding. 4, 33 In younger, healthier individuals with fewer risks for death, increased mortality from major bleeding may explain the findings. Further evidence from other study populations is needed to verify this interaction.
In this analysis, there were 583 deaths in total among rivaroxaban and apixaban users, which far exceeds prior observational analyses, each of which had fewer than 183 deaths among DOAC users. [11] [12] [13] However, our analysis, which included mortality information from both the SSA Death Master File and medical claim records, likely misclassified some individuals as living who actually died. The SSA Death Master File is missing up to 40% of deaths over our study period. 22 Under the assumption that missed deaths are non-differential with respect to treatment, this type of misclassification should lead to bias towards the null. Further, given the low mortality seen in our analysis, misclassification of some individuals as living who have died would be extremely unlikely to meaningfully impact our results. Captured in-hospital deaths based on medical claim records reduced the severity of this problem. Furthermore, the crude 6-month all-cause death rates in this study were 3.4, 2.0 and 2.7% among those with prescriptions for warfarin, rivaroxaban and apixaban, respectively. These rates are comparable with the crude all-cause death rates in the EINSTEIN-DVT and EINSTEIN-PE trials (2.2-2.4% among rivaroxaban and 2.1-2.9% among VKA users over the treatment period of 3-12 months), 2,3 the AMPLIFY trial (1.5% among apixaban and 1.9% among warfarin users over the 6-month treatment period), 4 an observational study of unprovoked VTE in Denmark (2.8% among rivaroxaban and 3.0% among warfarin users over 6 months) 11 and a multi-centre observational study of symptomatic DVT (0.3% among rivaroxaban and 2.9% among VKA users over 180 days). 12 A major limitation of observational research specifically when using claims data is the possibility of uncontrolled confounding (e.g. we cannot adjust for important lifestyle factors such as smoking and physical activity or over-thecounter medications such as aspirin), which can lead to a lack of exchangeability between treatment groups. While the assumption of no uncontrolled confounding is unlikely to be satisfied, we attempted to minimize bias due to confounding by including in our exposure models key demographic, co-morbidity, frailty and medication variables likely to be related to both treatment and mortality. We are reassured that uncontrolled confounding likely has not played a major role in our findings as our results are consistent with and extend results of randomized controlled trials (which randomize to control for confounding), as well as those of smaller observational studies. Further, individuals whose primary treatment for VTE were DOACs tended to be younger and have fewer co-morbid conditions than warfarin users and as such we would expect confounding to favour a lower mortality with DOACs, which we did not see. Additionally, there is no rationale why co-morbid conditions would less likely be documented for DOAC users than warfarin users. While we cannot exclude small differences in mortality by primary anticoagulant choice to treat VTE, these are not likely clinically significant based on our results as well as those of other studies.
Another limitation of this study was the limited power for detecting treatment-covariate interactions with respect to the risk of all-cause mortality. In particular, there was a low prevalence ( 20%) of some co-morbidities of interest, such as renal disease and liver disease, and so the precision of effect estimates was poor in these sub-groups. Future studies should continue to compare the safety of different oral anticoagulants in these specific sub-groups.
Strengths of this study include that it assesses the safety of oral anticoagulants for treatment of VTE in a nationwide sample of private health plan enrolees participating in routine clinical practice, includes a large number of rivaroxaban and apixaban users and is the first study to conduct head-to-head comparisons of DOACs on the risk of all-cause mortality among patients with VTE. Despite the limitations of administrative data, when used with rigorous analytic methods, they represent an efficient way to examine the comparative safety and effectiveness of different treatment strategies. 34 Randomized trials, in comparison, would need to be very large, and thus prohibitively expensive and time consuming, to capture a similar number of deaths among VTE patients. Furthermore, there is little incentive for drug manufacturers to fund new trials for head-to-head DOAC comparisons. 34 Non-administrative observational data sources also are typically too small to answer the questions posed here.
In conclusion, in this large sample of private insurance enrolees with a diagnosis claim for VTE and a pharmacy claim for an oral anticoagulant, risk of all-cause mortality was similar for the comparisons of warfarin and the DOACs rivaroxaban, and apixaban, and for head-to-head comparisons of the DOACs. The associations for comparisons of DOACs versus warfarin are in agreement with previous findings from clinical trials and small observational studies, while the findings for head-to-head DOAC comparisons provide new information on the safety of oral anticoagulants for the treatment of VTE.
What is known about this topic?
• Direct oral anticoagulants are non-inferior to warfarin for preventing recurrent venous thromboembolism. • Few studies have assessed the comparative effectiveness of oral anticoagulants with respect to risk of allcause mortality.
What does this paper add?
• Risk of all-cause mortality is similar for warfarin, rivaroxaban and apixaban prescribed for the primary treatment of venous thromboembolism. • Other criteria such as patient preference, cost, recurrent VTE risk or bleeding risk should be used to determine choice of anticoagulant.
